leisure time -WSS

leisure time

author：focus 2025-09-03 07:38:36 - browse：79573

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： A revolution in caring for preterm infants

leisure time

focus

WSS

Focused ultrasound for uterine fibroids: an uphill battle

Biohaven protein

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Health insurers say they are turning to AI to cut costs, improve care

Average age of first period drops to 11.9 years, study shows

Medicare to cover more brain scans related to Alzheimer’s drugs

focus

leisure time

focus

Medical records are filled with copy

Female surgeons have lower rates of long

Walensky prepares to leave CDC — and Congress — behind

There’s no way to know how good AI health technologies are

Continuity nursing helped my family in our darkest PICU moments

European regulators recommend Amylyx's ALS drug be rejected

Virginia high school admissions case could be legal follow

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Cancer drug shortages should be causing more outrage

iTeos Therapeutics debuts first data on TIGIT

knowledge

Dark money group runs ads on China biotech bill

Bernie Sanders bashes nonprofit hospitals over their tax breaks

What will save rural psychiatry services? Higher Medicaid payments

Scientists successfully use ultrasound imaging to map brain activity

Addiction doctors spar with methadone clinics over legislation

Childbirth

leisure time

leisure time

focus

focus